Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?

AIDS Res Hum Retroviruses. 1995 Sep;11(9):1131-3. doi: 10.1089/aid.1995.11.1131.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Amino Acid Sequence
  • Gene Products, env / genetics*
  • Gene Products, env / immunology*
  • Genes, env
  • HIV Antibodies
  • HIV Envelope Protein gp120 / genetics
  • HIV Envelope Protein gp120 / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control
  • HIV Infections / virology
  • HIV-1 / genetics*
  • HIV-1 / immunology*
  • HIV-1 / isolation & purification
  • Humans
  • Molecular Sequence Data
  • Neutralization Tests
  • Peptide Fragments / genetics
  • Peptide Fragments / immunology

Substances

  • AIDS Vaccines
  • Gene Products, env
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV envelope protein gp120 (305-321)
  • Peptide Fragments

Associated data

  • GENBANK/U28283
  • GENBANK/U28284
  • GENBANK/U28285
  • GENBANK/U28286
  • GENBANK/U28287
  • GENBANK/U28288
  • GENBANK/U28289
  • GENBANK/U28290
  • GENBANK/U28291
  • GENBANK/U28292
  • GENBANK/U28293
  • GENBANK/U28313
  • GENBANK/U28314
  • GENBANK/U28315
  • GENBANK/U28316
  • GENBANK/U28317
  • GENBANK/U28318
  • GENBANK/U28319
  • GENBANK/U28320